Wallachbeth capital announces closing of bioaffinity technologies, inc. $7.8 million initial public offering

Jersey city, n.j. , sept. 6, 2022 /prnewswire/ -- wallachbeth capital llc, a leading provider of capital markets and institutional execution services, announced today bioaffinity technologies, inc. ("bioaffinity" or the "company") (nasdaq: biaf, biafw), a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung, has completed its previously announced initial public offering ("ipo") of 1,282,600 units, each consisting of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share, for aggregate gross proceeds of approximately $7.8 million, prior to deducting underwriting discounts, commissions, and other offering expenses.
BIAF Ratings Summary
BIAF Quant Ranking